公开(公告)号：US20160279241A1

公开(公告)日：2016-09-29

申请号：US15184332

申请日：2016-06-16

Applicant: Genentech, Inc.

Inventor： Jakob Dupont ,  Cornelia Irl ,  Amreen Husain ,  Mika A. Sovak ,  Jing Yi ,  Hoa Nguyen

IPC: A61K39/395 ,  A61K31/282 ,  A61K9/00 ,  A61K31/337

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.

Abstract translation: 本发明涉及一般用抗VEGF抗体治疗疾病和病理状况。 更具体地，本发明涉及使用抗VEGF抗体治疗易患或诊断为癌症的患者，优选与一种或多种另外的抗肿瘤治疗剂组合用于治疗卵巢癌。

公开(公告)号：US20230226179A1

公开(公告)日：2023-07-20

申请号：US18149972

申请日：2023-01-04

Applicant: Genentech, Inc.

Inventor： Jakob Dupont ,  Cornelia Irl ,  Amreen Husain ,  Mika A. Sovak ,  Jing Yi ,  Hoa Nguyen

IPC: A61K39/395 ,  A61K31/282 ,  A61K31/337 ,  G06Q99/00 ,  C07K16/22 ,  A61K31/7068 ,  A61K9/00 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K31/282 ,  A61K31/337 ,  G06Q99/00 ,  C07K16/22 ,  A61K31/7068 ,  A61K39/3955 ,  A61K9/0019 ,  C07K16/3069 ,  A61K2039/54

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.

公开(公告)号：US20210052728A1

公开(公告)日：2021-02-25

申请号：US15930798

申请日：2020-05-13

Applicant: Genentech, Inc.

Inventor： Jakob Dupont ,  Cornelia Irl ,  Amreen Husain ,  Mika A. Sovak ,  Jing Yi ,  Hoa Nguyen

IPC: A61K39/395 ,  A61K31/282 ,  A61K31/337 ,  G06Q99/00 ,  C07K16/22 ,  A61K31/7068 ,  A61K9/00 ,  C07K16/30

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.

公开(公告)号：US20180344847A1

公开(公告)日：2018-12-06

申请号：US16059964

申请日：2018-08-09

Applicant: Genentech, Inc.

Inventor： Jakob Dupont ,  Cornelia Irl ,  Amreen Husain ,  Mika A. Sovak ,  Jing Yi ,  Hoa Nguyen

IPC: A61K39/395 ,  A61K31/282 ,  A61K31/337 ,  A61K31/7068 ,  C07K16/30 ,  C07K16/22 ,  A61K9/00 ,  G06Q99/00 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A61K9/0019 ,  A61K31/282 ,  A61K31/337 ,  A61K31/7068 ,  A61K39/3955 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/22 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/56 ,  G06Q99/00 ,  A61K2300/00

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.

公开(公告)号：US20170143826A1

公开(公告)日：2017-05-25

申请号：US15421184

申请日：2017-01-31

Applicant: Genentech, Inc.

Inventor： Jakob Dupont ,  Cornelia Irl ,  Amreen Husain ,  Mika A. Sovak ,  Jing Yi ,  Hoa Nguyen

IPC: A61K39/395 ,  C07K16/30 ,  A61K9/00 ,  A61K31/337 ,  A61K31/282

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.